Next Science (ASX:NXS) Long-Term Debt: A$7.73 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NXS Next Science Ltd ASX:NXS
25 GF Score
Price A$0.15
GF Value A$37.70
! 7 Warning Signs
View Full Analysis

What is Next Science Long-Term Debt?

Next Science ASX:NXS 25 Long-Term Debt is A$7.73 Mil as of Jun. 2025. GuruFocus rates ASX:NXS with a GF Score™ of 25/100 and a GF Value™ of A$37.70. The stock has 7 warning signs investors should review.

Next Science's Long-Term Debt for the quarter that ended in Jun. 2025 was A$7.73 Mil.

Next Science's quarterly Long-Term Debt increased from Jun. 2024 (A$0.86 Mil) to Dec. 2024 (A$2.85 Mil) and increased from Dec. 2024 (A$2.85 Mil) to Jun. 2025 (A$7.73 Mil).

Next Science's annual Long-Term Debt stayed the same from Dec. 2022 (A$0.00 Mil) to Dec. 2023 (A$0.00 Mil) but then increased from Dec. 2023 (A$0.00 Mil) to Dec. 2024 (A$2.85 Mil).

Next Science  (ASX:NXS) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Next Science Long-Term Debt Related Terms

Next Science Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Next Science's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Long-Term Debt Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 2.85

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 0.00 0.86 2.85 7.73
ASX:NXS
25GF Score
Next Science Ltd ASX:NXS
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$7.73 Mil mean?
Next Science (ASX:NXS) has a Long-Term Debt of A$7.73 Mil as of Jun. 2025.
Is Next Science's Long-Term Debt too high?
Next Science's current Long-Term Debt is A$7.73 Mil. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Long-Term Debt compare to GCAN and PTPI?
Next Science's Long-Term Debt of A$7.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Next Science's current Long-Term Debt is A$7.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Long-Term Debt of A$7.73 Mil. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Long-Term Debt is A$7.73 Mil. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Long-Term Debt is A$7.73 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Next Science (ASX:NXS) Overvalued in 2026?

Based on GuruFocus' analysis, Next Science stock appears to be undervalued. The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.

Key valuation signals for ASX:NXS:

  • Long-Term Debt: A$7.73 Mil
  • GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score

Get the complete analysis for ASX:NXS

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price
A$37.70
GF Value